saruparib (AZD5305) / AstraZeneca - LARVOL DELTA

First interim efficacy analysis of the Phase 1/2 PETRANHA trial of saruparib + androgen receptor pathway inhibitors (ARPI) in patients (pts) with metastatic prostate cancer (mPC) (ESMO 2025) - No abstract available

Clinical • Metastases • P1/2 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Saruparib: Data from P3 EvoPAR-Prostate01 trial (NCT06120491) for metastatic CSPC post 2026 (AstraZeneca) - H1 and Q2 2025 Results: Data from P1 ASCERTAIN trial (NCT05938270) for newly diagnosed prostate cancer in H1 2026

P1 data • P3 data • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Prostate Cancer

Saruparib + camizestrant: Data from P3 EvoPAR-Breast01 trial (NCT06380751) for HR+/HER2-negative advanced breast cancer post 2026 (AstraZeneca) - H1 and Q2 2025 Results

P3 data • Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology

Saruparib: Data from P1/2a PETRA trial (NCT04644068) for advanced solid malignancies post 2026 (AstraZeneca) - H1 and Q2 2025 Results: Data from P1/2a PETRANHA trial (NCT05367440) for metastatic prostate cancer post 2026

P1/2 data • Oncology • Prostate Cancer • Solid Tumor

A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: AstraZeneca

Biomarker • Monotherapy • New P1/2 trial • Oncology • Ovarian Cancer • Solid Tumor

PETRA: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1/2 | N=804 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2027 ➔ Jun 2027 | Trial primary completion date: Mar 2027 ➔ Jun 2027

Monotherapy • Trial completion date • Trial primary completion date • Biliary Cancer • Bladder Cancer • Breast Cancer • Cervical Cancer • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Genito-urinary Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Datopotamab deruxtecan plus PARP inhibition is highly synergistic in 2D and 3D ovarian cancer models (EACR 2025) - "This study provides a preclinical rationale for the clinical investigation of Dato-DXd in combination with PARPi olaparib or saruparib in OC."

Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA2 • CASP3 • CASP7 • HER-2 • TACSTD2

PARP INHIBITORS IMPAIR ERYTHROPOIESIS THROUGH P53 ACTIVATION (EHA 2025) - "While olaparib and niraparib primarily target PARP1 and PARP2, saruparib, which more specifically targets PARP1, has shown reduced hematotoxicity in preclinical models. In conclusion, our study demonstrates that PARPi, regardless of the PARP type they target, impair erythropoiesis primarily at late stages of differentiation by increasing apoptosis, reducing cell division and accelerating the erythroid differentiation. We identified P53 as a key player in this process. These findings offer novel insights into the molecular basis of PARPi-induced anemia."

Anemia • Gynecologic Cancers • Hematological Disorders • Hematological Malignancies • Oncology • ANXA5 • BAX • BRCA1 • BRCA2 • CD34 • CD36 • CDKN1A • ENG • HRD • PARP2 • SCARB1 • TP53

OVERCOMING VENETOCLAX RESISTANCE BY SELECTIVE PARP1 INHIBITION IN ACUTE MYELOID LEUKEMIA (EHA 2025) - "Background: Clinical relapse due to therapy resistance is common in acute myeloid leukemia (AML) patients treated with venetoclax (ven)-azacitidine (aza), and effective strategies to manage these patients are lacking. Selective PARP1 inhibition by saruparib amplifies apoptotic signaling induced by ven-aza leading to accumulation of DNA damage and cytotoxicity in venR AML cells both in vitro and in vivo. Thus, this presents a explorative therapeutic strategy to overcome venetoclax resistance in AML after dose refinement."

Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • ANXA5 • PARP2 • PTPRC

PETRANHA: Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - P1/2 | N=190 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Jul 2031 ➔ Apr 2031 | Trial primary completion date: Jul 2031 ➔ Apr 2031

Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Evopar prostate01 (NORDKONGRESS 2025) - "Contents of randomized, double-blind, placebo-controlled, multicenter phase III study with adaptive design to Saruparib vs. Placebo in combination with a new hormonal substance (NHA) after selection of testing in men with MHSPC. The results of the Phase III study ProPel showed a significant improvement in the RPF in MCRPC patients who received the combination of Olaparib and Abirateron, VS patients who only received abiraterone...In addition to the primary end point in the ITT population and the secondary endpoint overall survival, PFS2, TFST, Orr and others are examined. Stratification takes place according to BRCA/HRR status, the volume of illness and the NHA election of the test doctor."

BRCA • PARP2

BRCA2 reversion mutation-independent resistance to PARP inhibition through impaired DNA prereplication complex function. (PubMed, Proc Natl Acad Sci U S A) - "Mechanistically, prostate cells with impaired pre-RC activity displayed rapid resolution of olaparib-induced DNA damage as well as protection from replication fork degradation caused by Brca2 loss, providing insight into how Brca2-mutant cancer cells can escape cell death from replication stress induced by PARP inhibition in the absence of HR repair. Of note, a pharmacologic inhibitor that targets the CDT1/geminin complex (AF615) restored sensitivity to AZD5305, providing a potential translational avenue to enhance sensitivity to PARP inhibition."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA • BRCA2 • CDT1

AZD5305 hADME in Patients With Advanced Solid Malignancies (clinicaltrials.gov) - P1 | N=8 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

AZD5335, a folate receptor alpha-targeted ADC, enhances ovarian cancer treatment with bevacizumab, paclitaxel and/or carboplatin (AACR 2025) - "AZD5335, an FRα-targeting antibody conjugated to a topoisomerase 1 inhibitor (TOP1i) payload, is currently being investigated in the FONTANA Phase I/IIa clinical trial (NCT#05797168), either as a single agent or in combination with a PARP1-selective inhibitor (saruparib). A series of in vitro studies will also define the ADC/SOC drug interactions and further delineate underlying mechanisms driving enhanced efficacy. These studies inform our ongoing clinical development of AZD5335 in ovarian cancer."

Epithelial Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • FOLR1

Combined a B7-H3-targeting antibody-drug conjugate, 7MW3711, and PARP inhibitors synergistically potentiates the antitumor activity in B7-H3-positive cancers (AACR 2025) - "In vivo, mice bearing ovarian and SCLC tumor xenografts were treated with the combination of 7MW3711 and PARPi. Evaluation of the drug resistance ability in cell lines expressing P-gp revealed 7MW3711 exhibited > 3-fold more potent than DS7300 (B7-H3-directed DXd ADC), indicating that 7MW3711 has a lower efflux efficiency in drug-resistant strains. These data provide evidence for the potential utility of 7MW3711 combination with PARPi for treatment of B7-H3-expressing tumors and support the rationale for further clinical studies."

Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • H2AX

EvoPAR-PR02: A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (clinicaltrials.gov) - P3 | N=700 | Not yet recruiting | Sponsor: AstraZeneca

New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA

The potent and selective PARP1 inhibitor and trapper SNV1521 exhibits combination activity with targeted and chemotherapeutics (AACR 2025) - "When comparing with the target efficacious concentration using a BRCA2-deficient cell line versus the NOEL for suppression of heme progenitors, SNV1521 showed an expanded margin versus either olaparib or saruparib...In a PDX model of breast cancer, the combination of topotecan with SNV1521 showed deeper tumor regression than either agent alone. Moreover, this activity showed durable anti-tumor activity after cessation of dosing. In summary, these data support the continued clinical development of SNV1521 as monotherapy and also in combination with drugs that are mechanistically synergistic but cannot be effectively combined with less selective PARP1 inhibitors because of overlapping toxicities."

Breast Cancer • Oncology • Solid Tumor • BRCA • BRCA2 • PARP2

XL309 is a potent, selective, and orally bioavailable USP1 inhibitor active as monotherapy and in combination with PARP inhibitors or irinotecan (AACR 2025) - P1 | "XL309 also elicited durable tumor regression in combination with saruparib and irinotecan in a CDX model, and with olaparib in a PDX model... XL309 is potentially a best-in-class USP1 inhibitor. PK assessments in conjunction with preclinical antitumor activity suggest that once daily oral administration of XL309 may achieve clinical activity alone or in combination with PARP inhibitors. XL309 is currently under investigation in a phase 1 first-in-human trial as monotherapy and in combination with olaparib in patients with advanced solid tumors (NCT05932862)."

Combination therapy • Monotherapy • Oncology • Solid Tumor • BRCA • BRCA1 • BRCA2 • PCNA • USP1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Targeting PARP for the prevention of BRCA1-deficient triple-negative breast cancers (AACR 2025) - "Both talazoparib and AZD5305 greatly suppress the growth of syngrafted BRCA1-deficient tumors in mice. AZD5305 also delayed the development of TNBC mammary tumors in MMTV-Cre/BRCA1co/co/p53+/- mice. Based on these results, in the future, PARP inhibitors may be effective drugs to reduce the risk of BRCA1-deficient breast cancer."

Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA1 • BRCA2 • PARP1

Combination of the PARP1-selective inhibitor saruparib with androgen receptor pathway inhibition provides combination benefit in preclinical models of prostate cancer with or without homologous recombination repair deficiency (AACR 2025) - P1 | "We evaluated the activity of the PARP1-selective inhibitor and trapper saruparib (AZD5305) in combination with the ARPi enzalutamide in a range of preclinical models in vitro and in vivo...Strikingly, this was not observed with the weaker PARP1 trapper veliparib, suggesting a requirement for trapping-induced DNA damage...These preclinical data demonstrate combination activity of saruparib and ARPi in HRRm as well as non-HRRm prostate cancer models and provide mechanistic evidence that combination benefit is driven by PARP1 trapping inducing DNA damage, and PARP1 inhibition and ARPi inhibiting the repair of this damage, leading to accumulation of cytotoxic genomic instability to the cancer cells. A clinical study ASCERTAIN (NCT05938270) has been initiated, where the focus is on collection of pre- and post- treatment biopsies from monotherapy and combinations of saruparib, and the ARPi darolutamide, with the aim of increasing further understanding of mechanisms of..."

Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • BRCA2 • CDK12 • HRD

A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician's Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/ HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B) (MBCC 2025) - P3 | "Participants will be randomized 2:2:1 to receive saruparib plus camizestrant, physician's choice CDK4/6i (abemaciclib, ribociclib, or palbociclib) plus physician's choice ET (fulvestrant, letrozole, anastrozole, or exemestane), or physician's choice CDK4/6i plus camizestrant, respectively. Status Participant enrollment is ongoing across 185 trial locations in 20 countries. Approximately 500 participants will be randomized across the 3 arms."

Clinical • Metastases • P3 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BRCA1 • BRCA2 • CDK4 • HER-2 • HRD • PALB2

S2409: Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study (clinicaltrials.gov) - P2 | N=900 | Not yet recruiting | Sponsor: SWOG Cancer Research Network | Initiation date: Mar 2025 ➔ Sep 2025

Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • SLFN11

CONCORDE: A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: University of Leeds | Trial primary completion date: Apr 2025 ➔ Mar 2026

Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

D5330C00004: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents (clinicaltrials.gov) - P1/2 | N=357 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Mar 2025 ➔ Dec 2025 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Breast Cancer • Colorectal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Head and Neck Cancer • HER2 Breast Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • ATM • BRCA • HER-2 • HRD • RAD51C • RAD51D